Board and exec changes at Agomab

Belgian biotech Agomab Therapeutics today announced the appointment of Dr Angelika Jahreis as an independent non-executive director to its board of directors, while Andrea Sáez will join Agomab’s executive leadership team as chief development officer.

As part of the next growth phase of the company, Paolo Michieli (founder and formerly chief scientific officer) and Torsten Dreier (previously chief development officer) will continue at Agomab as senior advisors and members of the Scientific Advisory Board (SAB).

Andrea Sáez was chief commercial/CSO at Origo Biopharma where she led the development of ALK5 inhibitor programs through preclinical and early clinical stages. Following the acquisition of Origo by Agomab in late 2021, she was head of portfolio at Agomab and led the development of AGMB-129 into Phase II trials. Ms Sáez initiated her academic career with a PhD in Immunology at the Pompeu Fabra University followed by postdoctoral research at Vall d’Hebron Hospital where she published on the therapeutic benefit of TGF-ß inhibitors in cancer. She gained deep understanding of regulatory affairs through supporting various biotechs in CMC, preclinical and clinical regulatory topics in her role as Regulatory Affairs Manager at a leading consultancy firm, after which she became R&D Director at Pangaea Oncology.